238 related articles for article (PubMed ID: 30218317)
21. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
[TBL] [Abstract][Full Text] [Related]
22. Revisiting detection of in-transit metastases in melanoma patients using digital
Zimmermann PA; Houdu B; Césaire L; Nakouri I; De Pontville M; Lasnon C; Aide N
Ann Nucl Med; 2021 Jun; 35(6):669-679. PubMed ID: 33770374
[TBL] [Abstract][Full Text] [Related]
23. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.
Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F
Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391
[TBL] [Abstract][Full Text] [Related]
24. EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program.
Lasnon C; Quak E; Le Roux PY; Robin P; Hofman MS; Bourhis D; Callahan J; Binns DS; Desmonts C; Salaun PY; Hicks RJ; Aide N
EJNMMI Phys; 2017 Dec; 4(1):17. PubMed ID: 28560574
[TBL] [Abstract][Full Text] [Related]
25. Pretherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography robust radiomic features predict overall survival in non-small cell lung cancer.
Mostafa R; Abdelsamie Kandeel A; Abd Elkareem M; Nardo L; Abdelhafez YG
Nucl Med Commun; 2022 May; 43(5):540-548. PubMed ID: 35190518
[TBL] [Abstract][Full Text] [Related]
26. Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?
Park HL; Yoo IR; Boo SH; Park SY; Park JK; Sung SW; Moon SW
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1021-1026. PubMed ID: 30756189
[TBL] [Abstract][Full Text] [Related]
27. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395
[TBL] [Abstract][Full Text] [Related]
28. Does PET SUV Harmonization Affect PERCIST Response Classification?
Quak E; Le Roux PY; Lasnon C; Robin P; Hofman MS; Bourhis D; Callahan J; Binns DS; Desmonts C; Salaun PY; Hicks RJ; Aide N
J Nucl Med; 2016 Nov; 57(11):1699-1706. PubMed ID: 27283930
[TBL] [Abstract][Full Text] [Related]
29. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer.
Lasnon C; Hicks RJ; Beauregard JM; Milner A; Paciencia M; Guizard AV; Bardet S; Gervais R; Lemoel G; Zalcman G; Aide N
Clin Nucl Med; 2012 Oct; 37(10):971-6. PubMed ID: 22899197
[TBL] [Abstract][Full Text] [Related]
30. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
31. Dual-time point 18F-FDG PET/CT scan for differentiation between 18F-FDG-avid non-small cell lung cancer and benign lesions.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Jul; 23(5):427-35. PubMed ID: 19437097
[TBL] [Abstract][Full Text] [Related]
32. How to harmonize SUVs obtained by hybrid PET/CT scanners with and without point spread function correction.
Ferretti A; Chondrogiannis S; Rampin L; Bellan E; Marzola MC; Grassetto G; Gusella S; Maffione AM; Gava M; Rubello D
Phys Med Biol; 2018 Nov; 63(23):235010. PubMed ID: 30474620
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.
Liu J; Dong M; Sun X; Li W; Xing L; Yu J
PLoS One; 2016; 11(1):e0146195. PubMed ID: 26727114
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study.
de Jong WK; van der Heijden HF; Pruim J; Dalesio O; Oyen WJ; Groen HJ
J Thorac Oncol; 2007 Nov; 2(11):1007-12. PubMed ID: 17975491
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.
Um SW; Kim H; Koh WJ; Suh GY; Chung MP; Kwon OJ; Choi JY; Han J; Lee KS; Kim J
J Thorac Oncol; 2009 Nov; 4(11):1331-6. PubMed ID: 19701106
[TBL] [Abstract][Full Text] [Related]
36. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
38. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Yamamoto T; Kadoya N; Shirata Y; Kaneta T; Koto M; Umezawa R; Ishikawa Y; Kubozono M; Sugawara T; Matsushita H; Abe K; Takeda K; Jingu K
Ann Nucl Med; 2015 Oct; 29(8):666-73. PubMed ID: 26040413
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy.
Imamura Y; Azuma K; Kurata S; Hattori S; Sasada T; Kinoshita T; Okamoto M; Kawayama T; Kaida H; Ishibashi M; Aizawa H
Lung Cancer; 2011 Jan; 71(1):49-54. PubMed ID: 20430470
[TBL] [Abstract][Full Text] [Related]
40. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]